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Abstract
Background: For adults, vitamin D intake of 100 mcg (4000 IU)/day is physiologic and safe. The
adequate intake (AI) for older adults is 15 mcg (600 IU)/day, but there has been no report focusing
on use of this dose.
Methods: We compared effects of these doses on biochemical responses and sense of wellbeing
in a blinded, randomized trial. In Study 1, 64 outpatients (recruited if summer 2001 25(OH)D <61
nmol/L) were given 15 or 100 mcg/day vitamin D in December 2001. Biochemical responses were
followed at subsequent visits that were part of clinical care; 37 patients completed a wellbeing
questionnaire in December 2001 and February 2002. Subjects for Study 2 were recruited if their
25(OH)D was <51 nmol/L in summer 2001. 66 outpatients were given vitamin D; 51 completed a
wellbeing questionnaire in both December 2002 and February 2003.
Results: In Study 1, basal summer 25-hydroxyvitamin D [25(OH)D] averaged 48 ± 9 (SD) nmol/
L. Supplementation for more than 6 months produced mean 25(OH)D levels of 79 ± 30 nmol/L for
the 15 mcg/day group, and 112 ± 41 nmol/L for the 100 mcg/day group. Both doses lowered plasma
parathyroid hormone with no effect on plasma calcium. Between December and February,
wellbeing score improved more for the 100-mcg/day group than for the lower-dosed group (1-tail
Mann-Whitney p = 0.036). In Study 2, 25(OH)D averaged 39 ± 9 nmol/L, and winter wellbeing
scores improved with both doses of vitamin D (two-tail p < 0.001).
Conclusion: The highest AI for vitamin D brought summertime 25(OH)D to >40 nmol/L, lowered
PTH, and its use was associated with improved wellbeing. The 100 mcg/day dose produced greater
responses. Since it was ethically necessary to provide a meaningful dose of vitamin D to these
insufficient patients, we cannot rule out a placebo wellbeing response, particularly for those on the
lower dose. This work confirms the safety and efficacy of both 15 and 100 mcg/day vitamin D3 in
patients who needed additional vitamin D.
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Background
Vitamin D nutrition can affect many aspects of health
because its metabolites function at many tissues. For oste-
oporosis prevention, the recent consensus is that
25(OH)D should exceed 72 nmol/L, and that adult con-
sumption of vitamin D should be about 25 mcg (1000
IU)/day [1]. A recommended dietary allowance (RDA) is
an intake "adequate to meet the known nutritional needs
of practically all healthy persons"[2]. According to this cri-
terion, there is still no scientific basis for an RDA for vita-
min D [3,4]. Controversies and ongoing concerns about
exceeding the safe upper limit (UL) for vitamin D are
probably why every major brand of multivitamins mar-
keted for older adults still contains less than the adequate
intake (AI) for adults >70 y. Resistance from manufactur-
ers may also stem from the fact that no clinical study has
yet specifically used 15 mcg (600 IU)/day of vitamin D3.
Vitamin D consumption in the amount of 100 mcg (4000
IU)/day is safe and physiologic for adults [5-7]. We have
characterized cross-sectional relationships between vita-
min D intakes, 25(OH)D, 1,25(OH)2D and PTH in endo-
crine outpatients [8]. Because circulating 25(OH)D was
insufficient in 25% of those patients, i.e. it was less than
40-nmol/L (<16 ng/mL), we wanted to offer them vitamin
D supplements and to determine whether there are
demonstrable differences between the use of the highest
current AI for vitamin D, and 100 mcg (4000 IU)/day.
In addition to monitoring their biochemical responses,
we enquired about participants' subjective aspects of well-
being. Among its many potential biological effects, vita-
min D nutrition may influence the brain, because brain
tissue possesses the enzyme that can produce
1,25(OH)2D, the biologically active form of vitamin D
[9,10]. The brain also possesses the appropriate receptors
to respond to this [11-13]. Electroencephalographic read-
ings change with season, especially in women [14]. One
study has reported that vitamin D supplementation
reduces depression in people with seasonal affective dis-
order better than does treatment with bright light [15].
One study of healthy students concluded that 10 or 20
mcg (400 or 800 IU)/day for only 5 days during winter
improved mood [16]. In men with prostate cancer, 50
mcg (2000 IU)/day vitamin D improved functionality and
quality of life [17]. In a large placebo-controlled, rand-
omized study that showed that fractures are prevented
with 20 mcg (800 IU)/day of vitamin D the authors also
reported that self-reported health improved significantly
for women, but not men [18]. In community-dwelling
healthy older American men with relatively high
25(OH)D levels who were randomized to 25 mcg (1000
IU)/day vitamin D or placebo, there was no effect on
health perception [19]. Likewise, in healthy American
women supplemented with 10 mcg (400 IU)/day vitamin
D or placebo, there was not difference in terms of per-
ceived mood changes with season [20]. In frail elderly, a
4-month randomized study of multivitamin supplemen-
tation (5 mcg (200 IU) /day vitamin D) failed to produce
an effect on wellbeing [21]. Hence, the season, dose, dura-
tion of the study, as well as the age, sex, general health of
the population studied and the 25(OH)D levels before
starting vitamin D can all play a role in whether an
improved sense of wellbeing is seen with vitamin D
supplementation.
Most patients in the northern USA presenting with diffuse
musculoskeletal symptoms exhibit 25(OH)D levels less
than 50 nmol/L (20 ng/mL) [22]. Women in Saudi Arabia
who present with low back pain commonly have
25(OH)D levels below 50 nmol/L, and in a Phase-2 study
design with no control group, they responded remarkably
well to treatment with oral 25(OH)D (5000 – 10,000 IU/
day) [23].
Depression scores at northern latitudes are generally worst
between December and February [24], coincident with
the nadir in 25(OH)D levels [25,26]. Thus, we chose these
months to compare the effects of two doses of supplemen-
tary vitamin D3 on biochemical responses and measures
of wellbeing of patients prescreened to be at high risk of
vitamin D insufficiency during winter.
Methods, Materials & Patients
Materials
Vitamin D3 doses were prepared in two concentrations:
700 mcg/mL and 95 mcg/mL. For this, we used crystalline
cholecalciferol (vitamin D3, USP Grade, Sigma, St Louis)
as previously described [27]. The crystalline vitamin D3
was dissolved in US-Pharmacopoeia-grade ethanol and
calibrated based on absorbance at 265 nm using a diode-
array spectrophotometer (Hewlett-Packard, Palo Alto,
CA), and based on the vitamin D molar extinction coeffi-
cient of 18,300 AU/mol/L. Thus, the UV absorptivity at
264 nm was 33.4 and 5.0 AU/cm path-length respectively
for the high and low dose.
Subjects (STUDY 1)
We previously reported on the biochemical characteristics
of thyroid clinic outpatients [8]. The following procedures
were followed in accordance with the ethical standards of
Mount Sinai Hospital on human experimentation,
approval was obtained from its human research ethics
committee, and each participant signed an informed con-
sent. Since current opinion is that desirable 25(OH)D
concentrations should exceed 70 nmol/L [1], we offered
to provide vitamin D to patients who, in spring and sum-
mer of 2001, had serum 25(OH)D <61 nmol/L, because
we expected these patients to develop 25(OH)D concen-
trations <40 nmol/L by the next winter, based on what weNutrition Journal 2004, 3:8 http://www.nutritionj.com/content/3/1/8
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knew of seasonal 25(OH)D changes in Toronto [25,28].
In late summer 2001, we sent letters to 333 of these
patients. Of those who signed the consent, approved by
the ethics-review committee of Mount Sinai Hospital, 46
completed at least 3 months of vitamin D supplementa-
tion (Table 1). Participants were unpaid volunteers. They
were not asked about intake of dietary supplements or
vitamins, because the eligibility criterion was a low
25(OH)D that demonstrated a need for supplementation.
Participants and their physician were blinded as to dose,
which was either 95 mcg/week (4200 IU/week; 600 IU/
day) or 700 mcg/week (28,000 IU/week; 4000 IU/day).
Doses were in 1 ml ethanol solution, added with a syringe
to a drink and consumed once per week as we have done
in previous studies [5,27]. Because vitamin doses are usu-
ally described in their daily amounts, we express the
weekly doses given here in their average daily amounts of
15 mcg/day or 100 mcg/day.
Biochemical Methods
We measured intact PTH on the DPC Immulite 2000 ana-
lyzer (DPC, Los Angeles, CA). Serum 25(OH)D was meas-
ured with the DiaSorin radioimmunoassay (Stillwater,
MN) with which our laboratory consistently reported
close to the mean of the DEQAS international proficiency
survey for this analyte [29]. Serum 1,25(OH)2D was
measured with the classic, calf-thymus receptor assay,
involving purification of analyte on Bond Elut C18OH
cartridges (Varian, Harbor City, CA) and an internal
standard to correct for losses during purification [30].
Questionnaire
To address the issue of whether the vitamin D supplemen-
tation affected sense of wellbeing, and in particular,
whether consumption of 100 mcg/day offers benefits
beyond those of consuming 15 mcg/day, the shipment of
vitamin D was accompanied by a brief questionnaire,
based on conventional depression-screening tools, and
incorporating questions relating to energy and mood:
1. Has your general ENERGY LEVEL been less than average
lately?
2. Has your MOOD been less than average lately?
3. Have you had problems sleeping, either too much or
too little?
4. Have you lost interest or pleasure in things you nor-
mally enjoy doing?
5. Have you had a decrease in your ability to concentrate?
6. Have you lost/gained weight?
The wellbeing score for Study 1 was the total number of
"YES" responses to these questions. A lower score (out of
6) reflected "better" wellbeing.
For those patients willing to continue taking the vitamin
D, the dose originally assigned was continued through the
winter 2002–2003, thereby overlapping their vitamin D
supplementation with the patients in Study 2, and com-
pleting the same questionnaires as the patients in Study 2.
Of the original 93 subjects who initially consented, 46
patients continued taking vitamin D3 through to Novem-
ber 2002.
STUDY 2
At the end of summer, 2002, more patients of the outpa-
tient endocrinology clinic were selected, this time based
on 25(OH)D levels that had been measured as <51 nmol/
L, and who had not participated previously. At the begin-
ning of November 2002, invitation letters were mailed to
324 patients along with a consent form, and a new ques-
tionnaire. Of these, 14 were returned as changed mailing
addresses, 243 did not respond. We received 67 returned,
signed consents with completed questionnaires within
Table 1: Statistical analysis of Study 1 scores of wellbeing (Winter 2001–2002).
Intent-to-treat analysis Per-protocol analysis
Dose of Vitamin D N Age N
mcg/day (IU/day) Total in group, 
(% female)
December 2001
Score out of 6;
mean (SD)
February 2002
Score out of 6;
mean (SD)
Total in group,
(% female)
December 2001
Score out of 6;
mean (SD)
February 2002
Score out of 6;
mean (SD)
15 (600) 32 (80%) 53 (14) 2.2 (2.0) 2.3 (2.3) 16 (80%) 2.4 (2.2) 2.3 (2.4)
100 (4000) 32 (83%) 55 (9) 2.0 (2.3) 1.1 (1.8) a 21 (83%) 1.5 (2.2) 1.0 (1.5) bc
a February scores for 100 mcg (4000 IU)/day were lower (better) than in the 15 mcg (600 IU)/day group by two-tail t-score p = 0.072; Mann-
Whitney p = 0.072; these 2-tail values are equivalent to 1-tail significance. 
b Paired t-test, December score vs February Score p = 0.097; or non-parametric Sign test, p = 0.109. 
c Difference between dose groups by t-test p = 0.047; by Mann-Whitney test p = 0.072 (this 2-tail value is equivalent to 1-tail significance)Nutrition Journal 2004, 3:8 http://www.nutritionj.com/content/3/1/8
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the allotted time period (approximately 2 wks from mail-
ing) (Figure 1).
Upon receipt of the completed consent, each patient was
randomized as before. Ten questions were added to the
Flowchart showing numbers of patients during the duration of these studies Figure 1
Flowchart showing numbers of patients during the duration of these studies.
333 Invitation Letters Sent in 
Summer 2001; 
criterion 25(OH)D  <61 nmol/L
93 Signed Consents 
Received,  patients 
randomized, and 1st
questionnaire completed
46 Continue with the 
study
324 Invitation Letter Sent in 
Summer 2002 to new patients; 
criterion 25(OH)D  <51 nmol/L
66 Signed Consents 
Received,  patients 
randomized, and 1st
questionnaire completed
31 Continuers 
Complete  Both 
Questionnaires of  
Winter 2002-3
51 New Participants 
complete both 
Questionnaires of  
Winter 2002-3
37 Patients completed both 
Questionnaires of Winter 
2001-2; i.e. per protocol
SUMMER 
2001
(Study 1)
NOVEMBER 
2002
(Study 2)
FEBRUARY 
2003 Nutrition Journal 2004, 3:8 http://www.nutritionj.com/content/3/1/8
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questionnaire, based upon the seasonal health question-
naire of Thompson and Cowan [31]:
7. Has your GENERAL HEALTH been less than average
lately?
8. Have you felt less rested upon waking from sleep lately?
9. Have you experienced a down feeling or inappropriate
guilt?
10. Have you felt less socially active lately?
11. Have you been indecisive lately?
12. Have you felt less productive or less creative lately?
13. Has your appetite increased or decreased?
14. Have you experienced any cravings for carbohydrates
(bread, pasta, rice, sugary foods), more than normal?
15. Has it been more difficult to deal with daily stress?
16. Have you felt irritable or anxious lately?
The wellbeing score for Study 2 was the total number of
"YES" responses to these questions, with a lower score
(out of 16) reflecting "better" wellbeing. This was mailed
at recruitment and in February 2003.
Statistical analysis
Statistical analysis and graphical presentation were carried
out using SPSS version 11 (SPSS, Inc., Chicago, IL). As rec-
ommended by Jones et al, analyses pertaining to wellbe-
ing were done and presented using both the intent-to-
treat approach (all available data), as well as per-protocol,
using only data for patients completing both December
and February questionnaires [32]. For each of these, statis-
tical analyses were done using both parametric, t-test
comparisons, and equivalent non-parametric approaches,
as specified in the following results section. For the well-
being score of Table 2, the null hypothesis had been one
tailed, i.e. that the higher dose would improve scores com-
pared to the lower dose. Thus, although all p-values are
presented here as 2-tailed, a one-tail null hypothesis was
disproved if the 2-tail p < 0.1 for differences in the direc-
tion expected a-priori. Statistical analyses of longitudinal
biochemical data are presented here as parametric assess-
ments, using ANOVA. If ANOVA indicated that significant
differences existed for the biochemistries, we performed
2-tail paired-t-tests because these were comparisons
defined a priori, and not post-hoc comparisons. i.e. Since
25(OH)D levels had been expected to be higher after
months of supplementing with vitamin D, the unexpected
observation would have been to see no difference (i.e.
beta error), the risk of which would have been increased
with Bonferroni or Dunnett comparisons. Mean values
are given with ±SD values. Correlation of wellbeing vs
months on dose was done with Spearman's rank-order
correlation coefficient, which measures association at the
ordinal level.
Table 2: Statistical analysis of Study 2 scores of wellbeing (Winter 2002–2003).
Intent-to-treat analysis  Per-protocol analysis
Dose of Vitamin D N Age N
mcg/day (IU/day) Total in group, 
(% female)
yr (SD) 25(OH)D nmol/
L (SD)
December
2002 Score
(out of 16)
February
2003
Score
(out of 16)
Total in 
group,
(% female)
December
2002 Score
(out of 16)
February
2003 Score
(out of 16)
CONTINUERS FROM STUDY 1 (on Vit D since previous year)
15 (600) 22 (77%) 54 (14) 69 (26) 7.2 (4.5) 4.4 (3.4) 15 (73%) 6.9 (4.8) 4.4 (3.4) b
100 (4000) 24 (84%) 56 (9) 126 (45) a 4.4 (4.4) a 4.0 (3.7) 16 (88%) 4.6 (4.6) 4.0 (3.7)
NEW PATIENTS FOR STUDY 2
15 (600) 33 (68%) 48 (13) 39 (9) 8.0 (5.2) 5.4 (4.3) 25 (64%) 8.7 (5.5) 5.4 (4.3) b
100 (4000) 33 (85%) 50 (14) 39 (9) 8.4 (5.5) 3.9 (3.6) c 26 (89%) 8.1 (5.6) 3.9 (3.6) bc
a Different from 15 mcg (600 IU)/day group (the value above the mean marked by this footnote) by t-test p < 0.04; lower (better) than in the 600 
IU/day group by Mann-Whitney p = 0.039.
b Paired t-test, December score vs February Score (the value to the left of the mean marked by this footnote) p < 0.012; also significant by the non-
parametric equivalent to paired t-test, the Wilcoxan test, p < 0.012.
c For New patients, low vs high dose group, 2-tail unpaired t test p = 0.188; Mann-Whitney p = 0.183; i.e. not significantly different.Nutrition Journal 2004, 3:8 http://www.nutritionj.com/content/3/1/8
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Results
Study 1. Biochemical responses
Results of biochemical tests are presented in Figure 2. For
those patients in whom biochemistry data were tested
within 2–6 months after starting vitamin D, both doses
increased 25(OH)D significantly, with higher levels in the
higher vitamin D dose group than in the lower dose
group. In both groups, statistically significant suppression
of PTH was detected only after 6 months of supplementa-
tion. While mean PTH was slightly lower for the 100 mcg/
day group, PTH was not significantly different between
dose groups. There were no significant differences in
serum total or plasma ionized calcium concentrations,
either over time, or between groups. There were no signif-
icant differences or changes in 1,25(OH)2D concentra-
tions between groups, or over time. Information relevant
to determining nutrient intake requirements for adults is
indicated by the bottom whiskers for 25(OH)D concen-
tration measured beyond 6 months: 15 mcg (600 IU)/day
resulted in average 25(OH)D concentrations of 79 (±30
SD) nmol/L with a minimum non-outlier value of 44
nmol/L; 100 mcg (4000 IU)/day resulted in average
25(OH)D concentrations of 112 (±41 SD) nmol/L with a
minimum non-outlier value of 69 nmol/L (note that dur-
ing winter, 25(OH)D levels should be lower than the
summer/fall values presented for data >6 mo beyond the
start of treatment).
Compared to the high-dose group, the median increase in
25(OH)D per mcg vitamin D intake was significantly larger
in the lower dose group (p = 0.011, using the Mann-Whit-
ney test; p = 0.003, using the t-test). For the lower dose
group, the median 25(OH)D increase per mcg of vitamin
D dose was 2.2 nmol/L/mcg/d, (25th and 75th percentile
values were 0.6, 4.1 nmol/L/mcg/day respectively). For
the higher dose group, the median 25(OH)D increase was
0.6 nmol/L/mcg/day (25th and 75th percentile values
were 0.4, 0.9 nmol/L/mcg/day respectively).
Study 1 Effects on wellbeing (winter 2001–2002)
Table 1 summarizes the scores for wellbeing, based on six
questions. For the patients enrolled in Study 1, mean
25(OH)D concentrations prior to December 2001 were
49 (±9 SD) nmol/L for the higher dose group, and 46 (±9
SD) nmol/L for the lower dose group (Figure 2). Based on
the conventional two-tail analysis, none of the compari-
sons between doses or between December and February
was statistically significant. However, the hypothesis at
the outset of this research was the one-tailed question of
whether the higher dose of vitamin D has a better effect on
wellbeing than the lower dose. Therefore, we conclude
from Study 1, with 95% confidence (based on 2-tail p <
0.1), that 100 mcg (4000 IU)/day of vitamin D did result
in a significantly greater improvement in wellbeing, com-
pared to the effect of 15 (600 IU)/day. This statistical con-
clusion was the same whether the analysis was based on
the intention-to-treat analysis (analyses on the left side of
Table 1) or per protocol analysis (analyses on the right
side of Table 1), and the statistical conclusion was the
same with either parametric or nonparametric statistical
analysis.
Study 2 Effect on wellbeing (winter 2002–2003)
Table 2 summarizes the results for wellbeing, based on 16
questions. For each dose group of Study 2, 25(OH)D
mean concentration prior to December 2002 was 39 (±9
SD) nmol/L. Wellbeing improved from December to Feb-
ruary for all new patients enrolled in the study (p <
0.001); wellbeing also improved during this time for the
lower-dose patients remaining on the protocol from the
previous year (p = 0.012). There was no statistically signif-
icant change for the group that had been consuming 100
mcg (4000 IU)/day since the previous year. However,
those consuming the higher dose for one year were
already statistically at a lower (better) score for wellbeing
at the beginning of December 2002 compared to the cor-
responding Study-1 lower-dose group (2-tail t-test, p =
0.039). We also compared the groups based on the subset
of six questions used in Study 1; this produced the same
statistical differences shown in Table 2 for all 16 ques-
tions. That is, in Study 2, and using the 6 questions that
were the basis of wellbeing in Study 1, both doses lowered
the total score, but this time, there was no difference in
effect between 15 mcg (600 IU)/day versus 100 mcg
(4000 IU)/day.
As a form of meta-analysis, to combine the wellbeing data
of both Study cohorts in these experiments, we have sum-
marized the data from Table 2 as box-plots in Figure 3.
This figure highlights interactions between the duration of
vitamin D supplementation, and wellbeing. After Month
0, the quartile values show that the response was greater
(lower score) with the higher dose than with the AI dose
of vitamin D. For the pooled data in the figure, the non-
parametric correlation of wellbeing vs months on vitamin
D indicated a significant decline (improvement in wellbe-
ing) for participants consuming 100 mcg (4000 IU)/day
(p = 0.002). However, for those consuming 15 mcg (600
IU)/day the correlation with time on the dose was not sta-
tistically significant.
Discussion
Since these were endocrine outpatients, we had expected
their general perception of wellbeing to be less than that
of the general population. Since older persons with
25(OH)D <50 nmol/L risk losing muscle strength [33]
and development of musculoskeletal pain [22,23], there
was reason to consider non-osteoporosis-related
responses to vitamin D in patients with such low
25(OH)D levels. From an ethical perspective, patientsNutrition Journal 2004, 3:8 http://www.nutritionj.com/content/3/1/8
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who are selected because of low 25(OH)D levels should
receive at least a meaningful amount of vitamin D
[34,35]. We provided at least the vitamin D AI for the old-
est age group, 15 mcg (600 IU)/day, because some of our
Biochemical responses to vitamin D3 supplementation of endocrine outpatients during one year Figure 2
Biochemical responses to vitamin D3 supplementation of endocrine outpatients during one year. Open bars indicate pre-sup-
plementation data; boxes with intermediate shading indicate data at 2–6 months; darkest boxes, indicate data after >6 months 
of vitamin D. By the second visit after starting vitamin D, plasma 25(OH)D was higher in those taking 100 mcg/day than in 
those taking 15 mcg/day (values marked b differ significantly from the group's baseline values marked a, p < 0.001, by paired t-
test). 25(OH)D values marked b differ significantly from each other, conventional Students t-test, p = 0.006). PTH values 
marked c differ significantly from the group's baseline value, p = 0.003; PTH values marked d differ significantly from the 
group's baseline value, p = 0.013.
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patients were older than 70 years, and because age does
not affect the 25(OH)D response to a dose of vitamin D
[8,36].
The greatest biochemical responses to the vitamin D
occurred after six months of supplementation. During fol-
low-up, there was no clear plateau in 25(OH)D (Figure 2).
Lack of a plateau may reflect season, because the final
samples for 25(OH)D in the figure were taken through
the summer and autumn, when 25(OH)D levels should
be higher than in winter. Differences between the first and
the third box of each cluster in Figure 2 reflect the effects
of the intervention, not the season, because these samples
had been collected about one year apart. Future studies of
vitamin D supplementation should take into account that
it may take a year to reach stable 25(OH)D levels.
Although previous work (including our own) has implied
that plateau levels of 25(OH)D can occur within five
months [5,37], the impression of a plateau reflects the
time pattern of sampling; i.e. samples taken at short time
intervals can give a false impression of a plateau.
Higher levels of 25(OH)D generally correlate with lower
concentrations of PTH [1,8]. The present data confirm
that both doses produced a significant suppression of
PTH. The box-plots in Figure 2 suggest a somewhat greater
PTH suppression with the higher dose of vitamin D, and
we attribute the lack of a statistical difference in PTH
between the dose groups to the relatively small sample
sizes in this study. In our cross-sectional study of 1741
such patients we observed steady decreases in PTH as
25(OH)D increased [8]. There was no evidence of a
change in plasma ionized calcium as a result of this rela-
tively long-term use of vitamin D at a relatively high dose
of 100 mcg (4000 IU)/day. We should point out that this
dose is not high in the physiologic context, because it
approximates what healthy men acquire daily, if they
work outdoors [7]. The present data extend the time-
frame for follow-up beyond what has been reported pre-
viously, and our focus was on patients who did require
additional vitamin D; this contrasts with earlier studies of
100 mcg (4000 IU)/day that involved healthy volunteers,
where most were already sufficient in vitamin D [5,7].
Lansdowne and Provost reported that 10 or 20 mcg (400
or 800 IU)/day of vitamin D, given for 5 days improved
the mood of healthy Australian students during winter
[16]. Their protocol provided a total of 100 mcg (4000
IU) vitamin D or less, which could not have produced a
detectable change in 25(OH)D concentrations. The
results we obtained in Study 1 indicated that the 100 mcg
(4000 IU)/day dose of vitamin D resulted in fewer affirm-
ative responses to questions that were mainly related to
depression. However, since statistical significance was
one-tailed – which we did regard as valid because the
effect was in the direction hypothesized beforehand – we
wanted to confirm the greater efficacy of the higher dose.
The next winter, the protocol was refined (Study 2) to
include a more stringent recruitment, requiring lower
summer 25(OH)D concentrations (<51 nmol/L) and
additional questions relating to wellbeing [31].
In Study 2, both dose groups exhibited highly statistically
significant improvement in wellbeing between December
2002 and February 2003. The only patients who did not
improve during the second winter were those who had
been maintained on the higher dose of vitamin D for the
12 months leading up to December 2002, and whose
wellbeing score had already improved during Study 1.
Overall, both studies presented here were consistent with
the expectation that higher vitamin D nutrition improves
sense of wellbeing. The relatively greater improvement
during Study 2 compared to Study 1 could be explained to
the lower initial 25(OH)D concentrations of Study 2. The
Cross-sectional presentation of the effect of duration of vita- min D supplementation on quartiles of well-being scores  obtained during winter 2002–2003 Figure 3
Cross-sectional presentation of the effect of duration of vita-
min D supplementation on quartiles of well-being scores 
obtained during winter 2002–2003. The boxes with solid 
perimeters indicate new, Study-2 patients; the boxes with 
dashed-line perimeter indicate patients who had been con-
suming their vitamin D since December the previous year 
(from Study 1). Shaded boxes indicate the data for February, 
2002. Spearman's non-parametric correlation of well-being vs 
months was significant and negative with the higher dose (p = 
0.002), but the correlation was not significant for the lower 
dose (p = 0.108). Statistical comparisons among these data 
are presented in Table 2.
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eventual wellbeing response of low-dose patients from
Study 1 may reflect a cumulative effect of their vitamin D
intake. Since there was no placebo group used in this
study, we cannot rule out other reasons for improvement.
Questionnaire portions of this research were carried out
entirely through the mail, with randomized blinded
doses, and minimal direct contact between personnel and
the participants; thus, it is not likely that investigator bias
played a role. The winter was more severe during Study 2,
so we doubt that weather would have explained the
improved wellbeing reported during Study 2.
In retrospect, the SF-36 questionnaire, which is acceptable
to the FDA as a measure of health outcome, would have
been better to assess wellbeing [38]. Nonetheless, simple
screening tools like ours do correlate with, and perform
about as well as more complex, well-validated question-
naires [39]. Therefore, it as unlikely that a different ques-
tionnaire would have affected the sorts of changes we
observed, or the conclusions about wellbeing in relation
to vitamin D.
Conclusions
The present studies are the first to demonstrate, specifi-
cally, the efficacy of the highest current AI for vitamin D.
They also demonstrate, in adults older than studied previ-
ously, the safety of longer-term vitamin D supplementa-
tion with 100 mcg/day. This work suffered from the
ethical constraint that participants should not receive a
placebo supplement. While this weakens the quality of
evidence about wellbeing, we considered it important to
report the findings, because they provide keys to the better
design of subsequent research into effects of vitamin D on
wellbeing. Patients known to have low 25(OH)D levels
should not be deprived of vitamin D, and by providing
these patients with the AI dose of vitamin D there seems
to have been moderate improvement in wellbeing, albeit
less of a response than with 100 mcg/day. To demonstrate
the largest absolute  effects of vitamin D on wellbeing,
investigators would be advised to focus on a population
with low initial 25(OH)D concentration <50 nmol/L.
However, the relative question of whether a higher dose of
vitamin D has a greater effect on wellbeing compared to
the AI requires firstly, a larger sample size than was avail-
able for either of the present studies, and secondly, a focus
on adults prescreened not to have the low initial 25(OH)D
concentrations that we had specified in Study 2.
This work provides a new perspective about the safety of
vitamin D. In the conventional sense, neither dose of vita-
min D affected serum calcium levels. However, safety is
also supported by the fact that reported wellbeing of
patients was not made worse by the consumption of the
higher dose (instead, it improved). If wellbeing had dete-
riorated in any way, this would have been accepted readily
as a reason to keep vitamin D intake recommendations
low. Although our work confirms the anti-depressant,
wellbeing effects reported with short-term intervention
and smaller doses of vitamin D [15-17], we found that
with the higher dose, these effects were sustained for the
longer term of one year – which seems unlikely to happen
if this were simply a placebo effect. Effects on wellbeing or
depressive symptoms should be important criteria for tar-
geting an RDA for vitamin D, and these still require fur-
ther study.
List of abbreviations
25-hydroxy-vitamin D or calcidiol, 25(OH)D; 1,25-dihy-
droxy-vitamin D or calcitriol, 1,25(OH)2D; adequate
intake, AI; micrograms, mcg (the Greek letter mu, µ, is not
used in this document because some software replaces it
with "m", causing a 1000-fold error in the dose); recom-
mended dietary allowance, RDA.
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